Data On SQNM’s T-21 Diagnostic Test To Act As A Catalyst
Analysts at Auriga reiterate their "hold" rating on Sequenom (NASDAQ: SQNM). The target price for SQNM is set to $4.
According to Auriga, Sequenom has reported its Q4 revenues ahead of the estimates, driven by impressive Mass-array sales. However, SQNM’s EPS fell short of the expectations due to lower-than-expected gross margins.
Auriga mentioned that the performance of SQNM’s stock has been impressive in the recent past due to the launch of the company’s diagnostic tests and the stabilizing core GA segment. The data on SQNM’s T-21 diagnostic test, expected later this year, may prove to be a major event for the company.
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We're Loving
